Total Payments
$10,257
2024 Payments
$1,251
Companies
45
Transactions
316
Medicare Patients
2,486
Medicare Billing
$331,178

Payment Breakdown by Category

Food & Beverage$4,528 (44.1%)
Consulting$4,043 (39.4%)
Travel$1,319 (12.9%)
Other$200.00 (1.9%)
Education$167.77 (1.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $4,528 288 44.1%
Consulting Fee $4,043 3 39.4%
Travel and Lodging $1,319 4 12.9%
Honoraria $200.00 1 1.9%
Education $167.77 20 1.6%

Top Paying Companies

Company Total Records Latest Year
Incyte Corporation $4,273 11 $0 (2023)
AstraZeneca Pharmaceuticals LP $1,650 27 $0 (2024)
Novartis Pharmaceuticals Corporation $568.88 44 $0 (2020)
Genentech USA, Inc. $522.19 33 $0 (2024)
Merck Sharp & Dohme Corporation $241.29 18 $0 (2020)
Janssen Biotech, Inc. $216.52 14 $0 (2023)
Boehringer Ingelheim Pharmaceuticals, Inc. $212.11 19 $0 (2019)
Novocure GmbH $200.00 1 $0 (2022)
Exelixis Inc. $194.11 15 $0 (2019)
E.R. Squibb & Sons, L.L.C. $184.17 14 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2024 $1,251 3 AstraZeneca Pharmaceuticals LP ($1,225)
2023 $4,236 8 Incyte Corporation ($4,217)
2022 $269.76 2 Novocure GmbH ($200.00)
2021 $136.92 2 GlaxoSmithKline, LLC. ($125.00)
2020 $82.30 6 Amgen Inc. ($19.86)
2019 $1,119 66 Genentech USA, Inc. ($226.11)
2018 $1,727 120 Novartis Pharmaceuticals Corporation ($275.61)
2017 $1,435 109 Novartis Pharmaceuticals Corporation ($227.23)

All Payment Transactions

316 individual payment records from CMS Open Payments — Page 1 of 13

Date Company Product Nature Form Amount Type
12/12/2024 Genentech USA, Inc. Columvi (Biological), Gazyva, Lunsumio Food and Beverage In-kind items and services $26.35 General
Category: BioOncology
11/25/2024 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $825.00 General
02/19/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Consulting Fee Cash or cash equivalent $400.00 General
Category: Oncology
12/27/2023 Janssen Biotech, Inc. DARZALEX (Biological) Food and Beverage In-kind items and services $19.03 General
Category: Oncology
03/31/2023 Incyte Corporation Food and Beverage Cash or cash equivalent $34.55 General
03/16/2023 Incyte Corporation Consulting Fee Cash or cash equivalent $2,818.00 General
03/16/2023 Incyte Corporation Travel and Lodging Cash or cash equivalent $229.00 General
03/16/2023 Incyte Corporation Travel and Lodging Cash or cash equivalent $229.00 General
03/16/2023 Incyte Corporation Travel and Lodging Cash or cash equivalent $222.68 General
03/16/2023 Incyte Corporation Food and Beverage Cash or cash equivalent $46.15 General
02/24/2023 Incyte Corporation Travel and Lodging Cash or cash equivalent $637.92 General
11/01/2022 AstraZeneca Pharmaceuticals LP ENHERTU (Biological) Food and Beverage In-kind items and services $69.76 General
Category: Oncology
01/19/2022 Novocure GmbH Honoraria Cash or cash equivalent $200.00 General
12/08/2021 GlaxoSmithKline, LLC. ZEJULA (Drug) Food and Beverage In-kind items and services $125.00 General
Category: ONCOLOGY
06/01/2021 Gilead Sciences, Inc. Education In-kind items and services $11.92 General
09/03/2020 E.R. Squibb & Sons, L.L.C. OPDIVO (Biological) Education Cash or cash equivalent $11.66 General
Category: Oncology
02/11/2020 Amgen Inc. Prolia (Biological), XGEVA Food and Beverage In-kind items and services $19.86 General
Category: Bone Health
02/06/2020 Merck Sharp & Dohme Corporation KEYTRUDA (Biological), LENVIMA Food and Beverage In-kind items and services $11.78 General
Category: ONCOLOGY
01/21/2020 Seagen Inc. PADCEV (Biological) Food and Beverage In-kind items and services $13.52 General
Category: Oncology
01/14/2020 Novartis Pharmaceuticals Corporation PIQRAY (Drug) Food and Beverage In-kind items and services $13.00 General
Category: ONCOLOGY
01/11/2020 Celgene Corporation Pomalyst (Drug) Food and Beverage Cash or cash equivalent $12.48 General
Category: Hematology
11/21/2019 AstraZeneca Pharmaceuticals LP IMFINZI (Drug) Food and Beverage In-kind items and services $19.52 General
Category: Oncology
11/19/2019 PFIZER INC. IBRANCE (Drug), TALZENNA Food and Beverage In-kind items and services $13.62 General
Category: ONCOLOGY
11/14/2019 Genentech USA, Inc. TECENTRIQ (Biological) Food and Beverage In-kind items and services $11.94 General
Category: BioOncology
11/14/2019 Genentech USA, Inc. TECENTRIQ (Biological) Food and Beverage In-kind items and services $5.16 General
Category: BioOncology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 6 643 1,173 $538,987 $99,544
2022 7 647 1,048 $419,848 $92,803
2021 7 609 971 $307,623 $81,664
2020 6 587 888 $224,461 $57,167
Total Patients
2,486
Total Services
4,080
Medicare Billing
$331,178
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 213 446 $238,610 $44,208 18.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 286 565 $215,265 $37,335 17.3%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 80 80 $52,080 $10,422 20.0%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 28 34 $19,394 $4,273 22.0%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 14 26 $7,720 $2,321 30.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 22 22 $5,918 $984.02 16.6%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 184 374 $173,536 $40,172 23.1%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 268 464 $154,512 $31,463 20.4%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 78 78 $44,070 $11,076 25.1%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 24 27 $14,013 $3,968 28.3%
99443 Telephone medical discussion with physician, 21-30 minutes Facility 2022 51 63 $20,979 $3,668 17.5%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2022 15 15 $6,420 $1,418 22.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 27 27 $6,318 $1,038 16.4%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 263 516 $144,996 $36,803 25.4%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 121 216 $81,648 $23,813 29.2%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 75 75 $39,975 $10,607 26.5%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 74 84 $16,296 $3,651 22.4%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Facility 2021 45 48 $9,555 $2,850 29.8%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 16 17 $8,823 $2,661 30.2%
99204 New patient outpatient visit, total time 45-59 minutes Facility 2021 15 15 $6,330 $1,281 20.2%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 185 311 $83,663 $17,163 20.5%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Facility 2020 175 256 $32,404 $16,008 49.4%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 113 195 $70,148 $15,676 22.3%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 38 38 $19,706 $4,930 25.0%
99213 Established patient office or other outpatient visit, typically 15 minutes Facility 2020 64 76 $13,830 $2,415 17.5%

About Dr. Than Aye, MD

Dr. Than Aye, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Lawton, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1104053792.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Than Aye, MD has received a total of $10,257 in payments from pharmaceutical and medical device companies, with $1,251 received in 2024. These payments were reported across 316 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($4,528).

As a Medicare-enrolled provider, Aye has provided services to 2,486 Medicare beneficiaries, totaling 4,080 services with total Medicare billing of $331,178. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

Products in Payments

  • IMFINZI (Biological) $400.00
  • GILOTRIF (Drug) $212.11
  • IMFINZI (Drug) $204.53
  • Cabometyx (Drug) $194.11
  • KEYTRUDA (Biological) $193.83
  • OPDIVO (Biological) $154.20
  • ZEJULA (Drug) $153.29
  • MEKINIST (Drug) $139.79
  • Kadcyla (Biological) $131.13
  • DARZALEX (Biological) $130.24
  • Imbruvica (Drug) $128.10
  • AFINITOR (Drug) $122.13
  • BENDEKA (Drug) $114.29
  • JEVTANA (Drug) $111.56
  • Xtandi (Drug) $103.61
  • Perjeta (Biological) $102.24
  • Aranesp (Biological) $92.60
  • NINLARO (Drug) $92.01
  • TECENTRIQ (Biological) $88.90
  • PROMACTA (Drug) $88.36

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Lawton